2018 PDA Annual Meeting
Join Q2 Solutions at the 2018 PDA Annual Meeting and explore latest genomics and technological industry advancements
About This EventFrom our industry-leading genomics lab services and “Big Data” solutions, through biomarkers, precision medicine, companion diagnostics, esoteric testing, bioinformatics and analytics, to robust logistics and sample management, Q2 Solutions’ carefully orchestrated analyses approach can partner with you in choosing platforms and assays that will distinctly fit your needs.
We are committed to providing you with access to the most advanced technological solutions along with the support of our global project management staff so that you can quickly make important connections and proactively address issues to improve the quality of your studies.
Make plans to join Victor Weigman, our Translational Genomics Director, for his presentation “Industry Perspective on Genomic Profiling”, on Tuesday, March 20th at 9:00 – 9:30 am, to discover insights that can help you resolve some of your most complex biological challenges.
Schedule a meeting with Victor Weigman at this year’s PDA Annual Meeting to discuss how we can partner with you to help optimize your drug development process.
We look forward to meeting you in Orlando.
Director, Translational Genomics
Dr. Victor Weigman, Ph.D. is Director, Translational Genomics at Q2 Solutions, a Quintiles Quest Joint Venture, leading the group with a goal of continued facilitation of pre-clinical drug development through biomarker identification. Ongoing research revolves around the genomic profiling of solid tumors from both DNA and RNA approaches including the development of robust assays that can be leveraged as laboratory developed tests.
Dr. Weigman brings more than 10 years of biomarker discovery research with genomics, with a majority of them dedicated to Expression Analysis (EA), a Q2 Solutions Company. He has published 14 papers on biomarker identification and assay development and has contributed to the development and launch of several genomic CLIA Assays. Additionally, Dr. Weigman is involved in pharma partnerships for clinical trial development using genomic profiling technologies.
Dr. Weigman obtained his Ph.D. at the University of North Carolina in Biology and Bioinformatics within the Lineberger Comprehensive Cancer Center.